1. Home
  2. GHG vs ENGN Comparison

GHG vs ENGN Comparison

Compare GHG & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GHG

GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share

N/A

Current Price

$1.03

Market Cap

116.0M

ML Signal

N/A

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

N/A

Current Price

$1.90

Market Cap

117.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GHG
ENGN
Founded
2004
1999
Country
China
Canada
Employees
N/A
N/A
Industry
Hotels/Resorts
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
116.0M
117.2M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
GHG
ENGN
Price
$1.03
$1.90
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$21.08
AVG Volume (30 Days)
8.6K
684.7K
Earning Date
04-29-2026
06-11-2026
Dividend Yield
4.15%
N/A
EPS Growth
N/A
56.85
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$19.02
N/A
Revenue Next Year
$8.26
N/A
P/E Ratio
$5.76
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$1.40
52 Week High
$2.31
$12.25

Technical Indicators

Market Signals
Indicator
GHG
ENGN
Relative Strength Index (RSI) 33.51 54.21
Support Level N/A $1.67
Resistance Level $1.12 $1.95
Average True Range (ATR) 0.03 0.08
MACD -0.00 0.00
Stochastic Oscillator 29.63 68.42

Price Performance

Historical Comparison
GHG
ENGN

About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share

GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The Group reports its financial results in two operating segments: Hotel Business, which consists of leased-and-operated hotels and franchised-and-managed hotels operating under the hotel related brand, and Restaurant Business, which consists of leased-and-operated restaurants and franchised-and-managed restaurants operating under the brands of Da Niang and Bellagio. It derives maximum revenue from Hotel Business segment. It operates solely in China and generates all its revenue from China itself.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: